Prosthetic Joint Infections of Hip clinical trials at UCLA
1 research study open to eligible people
Showing trials for
TRL1068 for the Treatment of Prosthetic Joint Infection
open to eligible people ages 18-85
TRL1068 is expected to eliminate the pathogen-protecting biofilm in the prosthetic joint and surrounding tissue, thus making pathogens substantially more susceptible to established antibiotic treatment regimens. This Phase 2 study is designed to assess efficacy and safety of TRL1068 in combination with a DAIR (debridement, antibiotics, and implant retention) procedure for chronic prosthetic joint infections of the knee and hip, specifically, eliminating the need for the standard of care 2-stage exchange surgery, so that the original prosthesis can be retained.
Los Angeles 5368361, California 5332921 and other locations
Last updated: